BETHESDA, Md., April 1, 2014 (GLOBE NEWSWIRE) -- AREVA Med announced today the expansion of its Phase 1 clinical trial through collaboration with University of California San Diego Moores Cancer Center. Eligible patients with abdominal cancers will now be able to enroll in AREVA Med's clinical trial at UC San Diego.
In 2012, the Phase 1 clinical trial was launched at the University of Alabama at Birmingham's (UAB) Comprehensive Cancer Center. To date, 16 patients have received the study drug, and dose escalation continues. Early pharmacokinetics data have published in the journal Cancer Biotherapy and Radiopharmaceuticals.
Patient enrollment will take place at UC San Diego, covering the southern region and now the west coast. Patrick Bourdet, CEO of AREVA Med, underlined the importance of this expansion, noting that, "We are very pleased to be working with UC San Diego's world-class team. Their focus on comprehensive patient care and experience in oncology clinical trials highlights their dedication to developing novel therapies to address unmet needs."
More information at http://arevamed.areva.com/, @AREVAmed, or www.targetedtrials.com
MORE ABOUT AREVA MED
AREVA Med is an AREVA subsidiary specializing in the development of innovative therapies to fight cancer. AREVA Med has developed new processes for producing high purity lead-212 (²¹²Pb), a rare radioactive isotope that is currently at the heart of promising nuclear medicine research. In 2011, AREVA Med acquired Macrocyclics, the global leader in high performance chelating agent technology. AREVA Med is also associated with world-class scientific partners, such as the National Cancer Institute (NCI), the University of Alabama at Birmingham (UAB), and the French National Institute of Health and Medical Research (Inserm). In 2012, AREVA Med and Roche entered a strategic alliance to create novel advanced alpha radioimmunotherapy treatments to target and kill certain very aggressive types of cancer cells. For more information: http://arevamed.areva.com/ or www.targetedtrials.com.